BioCina and NovaCina Announce Strategic Merger to Create Integrated CDMO

NewSpring Capital Leads Financing as Kincell Bio and Cellipont Bioservices Merge to Form Kincellis Advanced Therapies

September 17, 2026

Healthcare Services

Kincell Bio and Cellipont Bioservices completed their merger to create Kincellis Advanced Therapies, a scaled U.S. contract development and manufacturing organization (CDMO) focused on cell therapies and other advanced modalities. The combined platform spans early development through commercial supply across multiple sites in Florida, North Carolina, and Texas, with the equity financing led by NewSpring Capital and debt support from J.P. Morgan.

GI Partners Completes Acquisition of Charles River’s CDMO and Cell Solutions Businesses, Forms Rose BioSolutions

May 8, 2026

Healthcare Services

GI Partners completed its acquisition of the Contract Development and Manufacturing Organization (CDMO) and Cell Solutions businesses from Charles River Laboratories, creating an independent advanced therapy manufacturing company, Rose BioSolutions. Rose BioSolutions will provide end-to-end cell and gene therapy development and manufacturing, covering plasmid DNA, viral vectors, cell therapy production, and cellular starting materials.

HAS Healthcare Advanced Synthesis Acquires Cerbios-Pharma to Form Leading CDMO Group

March 31, 2025

Healthcare Services

HAS Healthcare Advanced Synthesis SA (HAS) announced the planned acquisition of Cerbios-Pharma SA (Cerbios) to create a leading international CDMO group in Switzerland’s Ticino region. The combination brings complementary expertise in production, chemistry and biology, enabling expanded development and manufacturing services (including ADC-related capabilities), supported by 65 Equity Partners.

Bend Bioscience Unites CoreRx and Societal CDMO Under Single Bend Bioscience Brand

September 4, 2024

Pharmaceuticals

Bend Bioscience has unified CoreRx and Societal CDMO under the Bend Bioscience brand to form an integrated contract development and manufacturing organization (CDMO). The consolidation combines CoreRx’s formulation development expertise, Societal CDMO’s scalable cGMP manufacturing and packaging capabilities, and Bend Bioscience’s research and technology to offer end-to-end development-to-commercialization services across facilities in Bend, Oregon; Clearwater, Florida; and Gainesville, Georgia.

Asahi Kasei Medical to Acquire Bionova Scientific

April 14, 2022

Healthcare Services

Asahi Kasei Medical, through a U.S. subsidiary, has agreed to wholly acquire Bionova Scientific, LLC, a U.S.-based biopharmaceutical CDMO providing contract process development and GMP-compliant contract manufacturing services. The acquisition will add CDMO capabilities to Asahi Kasei Medical’s existing bioprocess business and broaden know-how-driven services for next-generation antibody drugs.

LGM Pharma Acquires Nexgen Pharma's Drug Product CDMO Business

July 23, 2020

Pharmaceuticals

LGM Pharma has acquired the formulation development and drug product contract manufacturing business of Nexgen Pharma, expanding LGM's CDMO capabilities and U.S.-based manufacturing footprint. Financial support for the transaction was provided by private equity firm New Harbor Capital; Nexgen Pharma sold its pharmaceutical CDMO unit to allow the company to focus on other healthcare segments.